lencana Anda Rentang 52M $129–$266 78% of range Peringkat Analis BUY 26 analysts Target Harga $294 +25% upside P/E 16.1 ROE 22.1% Margin Laba Bersih 20.4%

JAZZ Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $235.67
Kapitalisasi Pasar (MRQ) $15.27B
P/E (TTM) 16.1
EPS (TTM) $14.63
Pendapatan (TTM) $4.60B
ROE (TTM) 22.1%
D/E Utang/Ekuitas (MRQ) 0.9
Rentang 52M $129–$266

JAZZ Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Tentang Jazz Pharmaceuticals plc - Ordinary Shares Tinjauan perusahaan dari Wikipedia

05 · wikidata

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Company history and acquisitions

2010–2019

On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.

On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.

On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.

In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.

In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.

In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.

2020–present

In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.

In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.

Acquisition history

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

== References ==

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriPharmaceuticals karyawan2.890 negaraIE

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$4.27B
2016-12-31 → 2025-12-31
EPS$-5.84
2016-12-31 → 2025-12-31
Margin bersih20.4%
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun JAZZ rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) 16.1rata-rata 5T ≈-12.5 ≈-12.5 · ·
P/S (TTM) 3.3 · · ·
P/B (MRQ) 3.2 · · ·
Harga / FCF (TTM) 9.6 · · ·
Harga / Arus Kas (TTM) 9.2 · · ·
Harga / Nilai Buku Berwujud (MRQ) 19.8 · · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata -1.6%
Laporan Berikutnya Nov 03, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Agu 3, 2026 $5.71 $6.30 -9.4%
31 Maret 2026 $6.34 $4.66 36.1%
31 Des. 2025 $6.64 $6.65 -0.11%
30 Sep. 2025 $8.13 $6.04 34.7%
30 Juni 2025 $-8.25 $-7.76 -6.4%
31 Maret 2025 $1.68 $4.75 -64.6%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 14
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $4.27B$4.07B$3.83B$3.66B$3.09B$2.36B$2.16B$1.89B$1.62B$1.49B$1.32B$1.17B
R&D Expense ······$300M$227M$198M$162M$135M$85M
SG&A Expense $1.81B$1.39B$1.34B$1.42B$1.45B$854M$737M$684M$544M$503M$449M$406M
Operating Expenses $4.70B$3.35B$3.26B$3.72B$2.92B$1.99B$1.63B$1.28B$1.09B$896M$817M$977M
Operating Income $-430M$717M$579M$-66M$170M$378M$532M$615M$529M$592M$508M$196M
Interest Income $86M$106M$65M$12M$2M$11M$20M$17M$4M···
Other Non-op ··········$1M$9M
Pretax Income $-628M$470M$298M$-373M$-113M$275M$454M$529M$441M$532M$436M$152M
Income Tax $-272M$-91M$-120M$-159M$216M$34M$-73M$80M$-48M$135M$106M$94M
Net Income $-356M$560M$415M$-224M$-330M$239M$523M$447M$488M$397M$330M$58M
EPS (Basic) $-5.84$9.06$6.55$-3.58$-5.52$4.28$9.22$7.45$8.13$6.56$5.38$0.98
EPS (Diluted) $-5.84$8.65$6.10$-3.58$-5.52$4.22$9.09$7.30$7.96$6.41$5.23$0.93
Shares (Basic) 60,981,00061,838,00063,291,00062,539,00059,694,00055,712,00056,749,00059,976,00060,018,00060,500,00061,232,00059,746,000
Shares (Diluted) 60,981,00066,007,00072,066,00062,539,00059,694,00056,517,00057,550,00061,221,00061,317,00061,870,00063,036,00062,614,000
Neraca 26
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $1.39B$2.41B$1.51B$881M$591M$1.06B$637M$310M$386M$366M$989M$684M
Receivables $831M$717M$706M$651M$563M$396M$356M$264M$224M$234M$210M$186M
Inventory $417M$480M$597M$714M$1.07B$95M$79M$53M$43M$34M$19M$30M
Prepaid Expense $152M$177M$185M$92M$131M$62M$39M$25M$23M$25M$21M$13M
Other Current Assets $324M$262M$321M$267M$252M$152M$79M$68M$77M$29M$19M$21M
Current Assets $4.17B$4.63B$3.44B$2.61B$2.61B$2.84B$1.63B$1.23B$968M$748M$1.26B$1.02B
PP&E (Net) ·····$128M$132M$200M$170M$107M$86M$58M
PP&E (Gross) ·····$196M$187M$250M$211M$140M$109M$74M
Accum. Depreciation ·····$68M$55M$50M$41M$32M$24M$15M
Goodwill $1.83B$1.72B$1.75B$1.69B$1.83B$958M$920M$928M$948M$894M$657M$703M
Intangibles $4.43B$4.76B$5.42B$5.79B$7.15B$2.20B$2.44B$2.73B$2.98B$3.01B$1.19B$1.44B
Other Non-current Assets $99M$114M$67M$55M$41M$26M$48M$43M$16M$14M$9M$16M
Total Assets $11.66B$12.01B$11.39B$10.84B$12.30B$6.54B$5.54B$5.20B$5.12B$4.80B$3.33B$3.34B
Accounts Payable $122M$78M$103M$91M$100M$27M$46M$41M$24M$22M$22M$25M
Accrued Liabilities $1.03B$911M$794M$803M$666M$353M$270M$265M$199M$193M$164M$164M
Current Liabilities $2.24B$1.04B$1.54B$933M$809M$654M$364M$345M$294M$257M$227M$217M
Capital Leases $51M$39M$59M$72M$87M$140M$151M$0····
Deferred Tax $594M$677M$848M$944M$1.30B$130M$224M$309M$383M$557M$283M$375M
Other Non-current Liabilities $124M$87M$105M$107M$117M$101M$109M$219M$177M$113M$69M$38M
Long-term Debt $5.36B$6.11B$5.71B$5.72B$6.05B$2.09B$1.61B$1.60B$1.58B$2.03B$1.19B$1.34B
Common Stock $0$6.0K$6.0K$6.0K$6.0K$6.0K$6.0K$6.0K$6.0K$6.0K$6.0K$6.0K
Retained Earnings $646M$1.13B$879M$734M$830M$1.16B$1.07B$841M$918M$529M$303M$35M
AOCI $-569M$-948M$-842M$-1.13B$-400M$-134M$-223M$-198M$-141M$-317M$-267M$-122M
Stockholders' Equity $4.32B$4.09B$3.74B$3.09B$3.97B$3.66B$3.11B$2.76B$2.71B$1.88B$1.71B$1.37B
Liabilities + Equity $11.66B$12.01B$11.39B$10.84B$12.30B$6.54B$5.54B$5.20B$5.12B$4.80B$3.33B$3.34B
Shares Outstanding 61,400,00060,600,00062,255,00063,214,00061,633,00056,171,00056,140,00057,704,00058,898,00059,820,00061,305,00060,643,000
Arus Kas 12
Metrik Tren 202520242023202220212020201920182017201620152014
D&A $42M$33M$30M$30M$27M$19M$15M$15M$13M$12M$10M·
Stock-based Comp $291M$248M$227M$222M$189M$121M$111M$102M$107M$99M$92M$70M
Deferred Tax $-445M$-208M$-260M$-292M$69M$-137M$-237M$-89M$-226M$-41M$-68M$-49M
Amort. of Intangibles $655M$627M$608M$599M$526M$260M$355M$201M$152M$102M$98M$127M
Restructuring ··········$2M$2M
Operating Cash Flow $1.36B$1.40B$1.09B$1.27B$779M$900M$776M$799M$693M$592M$532M$408M
CapEx $59M$38M$24M$29M$28M$15M$40M$20M$29M$10M$36M$36M
Investing Cash Flow $-1.51B$-508M$-163M$-446M$-5.21B$-1.01B$-155M$-394M$-269M$-1.75B$-2M$-1.07B
Stock Repurchased $125M$311M$270M$54.0K$0$147M$301M$524M$99M$278M$62M$42M
Financing Cash Flow $-873M$21M$-305M$-529M$3.97B$528M$-294M$-479M$-409M$541M$-214M$711M
Net Change in Cash $-1.02B$907M$625M$290M$-466M$420M$328M$-76M$20M$-623M$305M$48M
Taxes Paid $122M$115M$178M·········
Per Saham 1
Metrik Tren 202520242023202220212020201920182017201620152014
EPS (TTM) $-5.84$8.65$6.10$-3.58$-5.52$4.22$9.09$7.30$7.96$6.41$5.23$0.93
Tingkat Pertumbuhan 7
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY 4.9%6.1%4.8%18.3%30.9%·······
Revenue CAGR 3Y 5.3%9.6%17.5%·········
Revenue CAGR 5Y 12.5%···········
EPS YoY ·41.8%··········
EPS CAGR 3Y ··13.1%·········
Net Income YoY ·35.0%··········
Net Income CAGR 3Y ··20.2%·········
Valuasi (TTM) 5
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $4.27B$4.07B$3.83B$3.66B$3.09B$2.36B$2.16B$1.89B$1.62B$1.49B$1.32B$1.17B
Net Income TTM $-356M$560M$415M$-224M$-330M$239M$523M$447M$488M$397M$330M$58M
P/E -29.114.220.2-44.5-23.139.116.417.016.917.026.9176.1
P / Tangible Book ·····18.3······
Earnings Yield -3.4%7.0%5.0%-2.2%-4.3%2.6%6.1%5.9%5.9%5.9%3.7%0.57%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $4.27B $4.07B $3.83B $3.66B $3.09B
Laba Bersih $-356M $560M $415M $-224M $-330M
EPS Dilusian $-5.84 $8.65 $6.10 $-3.58 $-5.52

Pemilik institusional (13F) 689 pengaju · $15.8B total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 689
Nilai yang dipegang $15.8B
Posisi baru 138
Posisi yang keluar 56
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
138 (+32 vs Kuartal sebelumnya) 56 (-21 vs Kuartal sebelumnya) 240 (+24 vs Kuartal sebelumnya) 188 (+19 vs Kuartal sebelumnya) +942K

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
BlackRock, Inc. $1.438.254.453 5.968.603 9,11% Saham
FMR LLC $1.110.709.035 4.609.326 7,04% Saham
VANGUARD GROUP INC $1.005.914.140 5.917.142 6,37% Saham
VANGUARD PORTFOLIO MANAGEMENT LLC $731.636.247 3.036.213 4,64% Saham
VANGUARD CAPITAL MANAGEMENT LLC $657.763.761 2.729.650 4,17% Saham
Capital World Investors $650.043.082 2.697.610 4,12% Saham
FRANKLIN RESOURCES INC $491.639.148 2.040.250 3,12% Saham
STATE STREET CORP $481.895.662 1.999.816 3,05% Saham
DIMENSIONAL FUND ADVISORS LP $412.909.300 1.713.592 2,62% Saham
FULLER & THALER ASSET MANAGEMENT, INC. $394.839.917 1.638.544 2,50% Saham
Bank of New York Mellon Corp $380.253.849 1.578.013 2,41% Saham
AQR CAPITAL MANAGEMENT LLC $359.935.093 1.522.568 2,28% Saham
GEODE CAPITAL MANAGEMENT, LLC $357.440.125 1.483.031 2,26% Saham
AMERIPRISE FINANCIAL INC $292.895.571 1.215.523 1,86% Saham
JPMORGAN CHASE & CO $276.634.191 1.160.786 1,75% Saham
BANK OF AMERICA CORP /DE/ $273.763.940 1.136.091 1,73% Saham
CITADEL ADVISORS LLC $242.578.716 1.006.676 1,54% Saham
Swedbank AB $233.281.128 968.092 1,48% Saham
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $192.606.598 799.297 1,22% Saham
MILLENNIUM MANAGEMENT LLC $184.072.164 763.880 1,17% Saham
UBS Group AG $182.381.760 756.865 1,16% Saham
VICTORY CAPITAL MANAGEMENT INC $165.478.678 686.719 1,05% Saham
NORGES BANK $158.279.458 656.843 1,00% Saham
MORGAN STANLEY $151.734.512 629.680 0,96% Saham
Mariner, LLC $146.630.968 608.615 0,93% Saham
RENAISSANCE TECHNOLOGIES LLC $135.442.731 562.073 0,86% Saham
Allianz Asset Management GmbH $131.345.759 545.071 0,83% Saham
MANUFACTURERS LIFE INSURANCE COMPANY, THE $129.891.746 539.037 0,82% Saham
NORTHERN TRUST CORP $123.222.660 511.361 0,78% Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $111.450.794 462.509 0,71% Saham
GMT Capital Corp $109.279.895 453.500 0,69% Saham
Boston Trust Walden Corp $106.779.349 443.123 0,68% Saham
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC $105.278.106 436.893 0,67% Saham
Zurcher Kantonalbank (Zurich Cantonalbank) $103.893.734 431.148 0,66% Saham
TWO SIGMA INVESTMENTS, LP $96.439.086 400.212 0,61% Saham
VANGUARD FIDUCIARY TRUST CO $95.008.929 394.277 0,60% Saham
SYSTEMATIC FINANCIAL MANAGEMENT LP $91.259.201 378.715 0,58% Saham
Nuveen, LLC $88.051.524 365.405 0,56% Saham
Sofinnova Investments, Inc. $88.036.221 365.341 0,56% Saham
Polaris Capital Management, LLC $79.270.937 328.966 0,50% Saham
AMERICAN CENTURY COMPANIES INC $77.695.234 322.427 0,49% Saham
GOLDENTREE ASSET MANAGEMENT LP $70.838.675 294.435 0,45% Saham
Qube Research & Technologies Ltd $70.056.003 290.725 0,44% Saham
GOLDMAN SACHS GROUP INC $67.434.009 279.844 0,43% Saham
FRONTIER CAPITAL MANAGEMENT CO LLC $66.815.854 277.279 0,42% Saham
Quantinno Capital Management LP $65.906.960 273.506 0,42% Saham
BANK OF MONTREAL /CAN/ $58.329.921 242.063 0,37% Saham
RAYMOND JAMES FINANCIAL INC $55.096.752 228.645 0,35% Saham
Tri Locum Partners LP $53.427.868 221.720 0,34% Saham
Invesco Ltd. $50.427.310 209.268 0,32% Saham

Tampilkan semua 689 pemilik institusional →

Aktivis & pemilik 5%+ 6 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 pengajuan 20 Juni 2014 · Pengajuan awal · SEC
KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 pengajuan 12 Maret 2013 · Pengajuan awal · SEC
Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 pengajuan 14 Maret 2012 · Pengajuan awal Struktur modal SEC
Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 pengajuan 30 Sep. 2011 · Pengajuan awal · SEC
Azur Pharma Limited 28 Sep. 2011 · Pengajuan awal M&A / penjualan SEC
Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC 28 April 2005 · Pengajuan awal M&A / penjualan SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 56 orang dalam · 18 pejabat · 20 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Renee D Gala President & CEO 8 Sep. 2026 S 143.394 0 1 $-486.060
Philip L Johnson EVP & Chief Financial Officer 30 Juni 2026 F 56.431 0 0 $0
Matthew P. Young EVP & CFO 6 Maret 2019 S 36.200 0 0 $0
Daniel N Swisher JR President and COO 5 Maret 2023 F 55.014 0 0 $0
Christopher J. Tovey EVP, COO & Managing Director E 5 Juli 2022 M 14.663 0 0 $0
Russell J. Cox EVP & COO 11 Des. 2017 M 102.821 0 0 $0
Neena M Patil EVP & Chief Legal Officer 10 Sep. 2026 S 47.671 0 14 $-11.500.359
Mary Elizabeth Henderson SVP, Technical Operations 8 Sep. 2026 F 23.815 0 2 $-1.418.523
Robert Iannone EVP, Global Head of R&D & CMO 27 Agu 2026 M 65.686 0 7 $-20.411.738
Samantha Pearce EVP, Chief Commercial Officer 5 Agu 2026 F 47.131 0 1 $-1.625.977
Patricia Carr SVP, Chief Accounting Officer 9 Maret 2026 S 6.512 0 7 $-2.458.091
Kim Sablich EVP, GM of U.S. 5 Juni 2023 D 28.478 0 0 $0
Finbar Larkin SVP, Technical Operations 6 Maret 2023 M 21.779 0 0 $0
MILLER MICHAEL PATRICK EVP, US Commercial 12 Maret 2020 S 22.118 0 0 $0
Paul Treacy SVP, Technical Operations 12 Agu 2019 S 16.418 0 0 $0
Iain Mcgill SVP, Europe & Rest of World 5 Maret 2019 F 24.938 0 0 $0
Karen J Wilson SVP, Finance & PAO 5 Maret 2019 F 18.385 0 0 $0
Suzanne Sawochka Hooper EVP & General Counsel 27 Feb. 2019 M 39.738 0 0 $0
Bruce C Cozadd Direktur 1 Sep. 2026 S 351.875 0 21 $-27.147.106
Patrick Kennedy Direktur 31 Agu 2026 F 6.452 0 0 $0
Mark Douglas Smith Direktur 31 Agu 2026 F 9.579 0 1 $-266.746
Jennifer E. Cook Direktur 31 Agu 2026 F 10.736 0 0 $0
Laura Hamill Direktur 31 Agu 2026 F 6.832 0 0 $0
Heather Ann Mcsharry Direktur 31 Agu 2026 F 18.199 0 2 $-1.089.119
Rick E Winningham Direktur 31 Agu 2026 F 9.466 0 2 $-1.656.873
Patrick G. Enright Direktur 31 Agu 2026 F 21.278 0 0 $0
Ted W Love Direktur 31 Agu 2026 F 2.389 0 0 $0
Norbert G Riedel Direktur 31 Agu 2026 F 6.923 0 1 $-655.680
Seamus Mulligan Direktur 5 Agu 2026 A 1.184.633 0 0 $0
Anne Oriordan Direktur 8 Agu 2025 F 16.500 0 0 $0
Peter Gray Direktur 14 Agu 2023 S 16.068 0 0 $0
Catherine A. Sohn Direktur 14 Agu 2023 S 14.868 0 0 $0
Elmar Schnee Direktur 5 Agu 2021 S 8.270 0 0 $0
Paul L Berns Direktur 5 Agu 2021 S 8.290 0 0 $0
Bryan C Cressey Direktur 9 Maret 2012 S 27.631 0 0 $0
Zilkha M Nathaniel Direktur 10 Maret 2011 A · 0 0 $0
Alexander E Albert Direktur 15 Agu 2008 A · 0 0 $0
Patel Jaimin Direktur 15 Agu 2007 A · 0 0 $0
Kenneth W O'Keefe · 2 Des. 2025 F 25.811 0 0 $0
Karen L. Smith · 5 Maret 2018 F 28.474 0 0 $0
Jeffrey K Tobias · 5 Maret 2015 F 38.484 0 0 $0
Fintan Keegan · 8 Juli 2014 M 31.750 0 0 $0
Kathryn E Falberg · 5 Maret 2014 F 133.387 0 0 $0
James C Momtazee · 13 Agu 2013 S 17.315 0 0 $0
Carol A Gamble · 9 Maret 2012 S 32.213 0 0 $0
Alan Sebulsky · 9 Maret 2012 S 54.355 0 0 $0
Samuel D Colella · 11 Jan. 2012 M 38.347 0 0 $0
Michael W Michelson · 11 Jan. 2012 M 13.885 0 0 $0
Mark G. Eller · 13 Agu 2011 M 4.151 0 0 $0
Michael A. Desjardin · 13 Agu 2011 M 14.574 0 0 $0
Janne Lt Wissel · 31 Mei 2011 J 48.544 0 0 $0
Joan Colligan · 30 Nov. 2010 J 14.424 0 0 $0
Robert M Myers · 30 Nov. 2010 J 156.898 0 0 $0
James B Tananbaum · 25 Agu 2010 A 21.366 0 0 $0
Samuel R Saks · 21 Jan. 2009 A 358.868 0 0 $0
Matthew K Fust · 28 Nov. 2008 J 58.948 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 62 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
IHE · iShares Trust 3,45% 232.236 SH 11 Sep. 2026 Harian
PJP · Invesco Exchange-Traded Fund Trust 2,85% 68.707 SH 1 Okt. 2026 Harian
XMMO · Invesco Exchange-Traded Fund Trust 2,31% 699.006 SH 1 Okt. 2026 Harian
PTH · Invesco Exchange-Traded Fund Trust 1,69% 26.762 SH 1 Okt. 2026 Harian
PILL · Direxion Shares ETF Trust 1,25% 1.023 NS 31 Juli 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0,98% 4.592 SH 1 Okt. 2026 Harian
RFG · Invesco Exchange-Traded Fund Trust 0,96% 13.808 SH 1 Okt. 2026 Harian
IVOG · VANGUARD ADMIRAL FUNDS 0,79% 61.910 SH 19 Agu 2026 Harian
PDP · Invesco Exchange-Traded Fund Trust 0,58% 36.818 SH 1 Okt. 2026 Harian
LSVD · ADVISORS' INNER CIRCLE FUND 0,58% 14.802 NS 31 Juli 2026 N-PORT
NUSC · Nushares ETF Trust 0,54% 27.352 NS 31 Juli 2026 N-PORT
QVMM · Invesco Exchange-Traded Fund Trust … 0,49% 8.679 SH 1 Okt. 2026 Harian
IVOO · VANGUARD ADMIRAL FUNDS 0,41% 101.353 SH 19 Agu 2026 Harian
MIDU · Direxion Shares ETF Trust 0,34% 921 NS 31 Juli 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0,32% 11.363 SH 19 Agu 2026 Harian
VBR · VANGUARD INDEX FUNDS 0,31% 867.777 SH 19 Agu 2026 Harian
VFMF · VANGUARD WELLINGTON FUND 0,28% 8.083 SH 19 Agu 2026 Harian
DFAS · Dimensional ETF Trust 0,28% 168.574 NS 31 Juli 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0,24% 19.561 SH 19 Agu 2026 Harian
IYH · iShares Trust 0,23% 34.871 SH 11 Sep. 2026 Harian
ESML · iShares Trust 0,22% 25.740 SH 11 Sep. 2026 Harian
DFAT · Dimensional ETF Trust 0,22% 123.193 NS 31 Juli 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,20% 166.548 SH 19 Agu 2026 Harian
SMMD · iShares Trust 0,20% 31.945 SH 11 Sep. 2026 Harian
RWK · Invesco Exchange-Traded Fund Trust … 0,18% 9.978 SH 1 Okt. 2026 Harian
VXF · VANGUARD INDEX FUNDS 0,17% 719.903 SH 19 Agu 2026 Harian
VB · VANGUARD INDEX FUNDS 0,17% 1.366.973 SH 19 Agu 2026 Harian
IWS · iShares Trust 0,14% 88.598 SH 11 Sep. 2026 Harian
WSML · iShares Trust 0,13% 3.647 SH 11 Sep. 2026 Harian
IWR · iShares Trust 0,11% 244.305 SH 11 Sep. 2026 Harian
EQAL · Invesco Exchange-Traded Fund Trust … 0,09% 3.138 SH 1 Okt. 2026 Harian
XT · iShares Trust 0,09% 13.710 SH 11 Sep. 2026 Harian
DFAC · Dimensional ETF Trust 0,08% 147.012 NS 31 Juli 2026 N-PORT
DFUV · Dimensional ETF Trust 0,08% 45.748 NS 31 Juli 2026 N-PORT
DCOR · Dimensional ETF Trust 0,05% 7.084 NS 31 Juli 2026 N-PORT
IUSG · iShares Trust 0,04% 55.258 SH 11 Sep. 2026 Harian
VONV · VANGUARD SCOTTSDALE FUNDS 0,04% 36.014 SH 19 Agu 2026 Harian
IWD · iShares Trust 0,04% 133.301 SH 11 Sep. 2026 Harian
DSI · iShares Trust 0,04% 8.411 SH 11 Sep. 2026 Harian
PRF · Invesco Exchange-Traded Fund Trust 0,04% 15.040 SH 1 Okt. 2026 Harian
IUS · Invesco Exchange-Traded Self-Indexe… 0,03% 1.369 SH 30 Sep. 2026 Harian
DFAU · Dimensional ETF Trust 0,03% 13.729 NS 31 Juli 2026 N-PORT
DYNF · BlackRock ETF Trust 0,02% 39.438 SH 11 Sep. 2026 Harian
DXUV · Dimensional ETF Trust 0,02% 467 NS 31 Juli 2026 N-PORT
IYY · iShares Trust 0,02% 2.648 SH 11 Sep. 2026 Harian
DFUS · Dimensional ETF Trust 0,02% 17.349 NS 31 Juli 2026 N-PORT
ITOT · iShares Trust 0,02% 81.293 SH 11 Sep. 2026 Harian
IWB · iShares Trust 0,02% 41.012 SH 11 Sep. 2026 Harian
VTI · VANGUARD INDEX FUNDS 0,02% 1.892.855 SH 19 Agu 2026 Harian
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 9.995 SH 19 Agu 2026 Harian
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 5.021 SH 19 Agu 2026 Harian
ESGV · VANGUARD WORLD FUND 0,02% 13.490 SH 19 Agu 2026 Harian
IWV · iShares Trust 0,02% 16.075 SH 10 Sep. 2026 Harian
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 49.429 SH 19 Agu 2026 Harian
OMFL · Invesco Exchange-Traded Self-Indexe… 0,01% 1.238 SH 1 Okt. 2026 Harian
NEAR · iShares U.S. ETF Trust 0,00% 200.000 SH 9 Sep. 2026 Harian
IJH · iShares Trust · 2.201.423 SH 11 Sep. 2026 Harian
IJK · iShares Trust · 363.871 SH 11 Sep. 2026 Harian
XJH · iShares Trust · 8.572 SH 8 Sep. 2026 Harian
ISCB · iShares Trust · 2.820 SH 11 Sep. 2026 Harian
ISCV · iShares Trust · 13.894 SH 11 Sep. 2026 Harian
SMMV · iShares Trust · 4.635 SH 19 Agu 2026 Harian

JAZZ Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 26 analis BELI
Target median $300.00 +27,3%
7 26,9% Beli Kuat
17 65,4% Beli
2 7,7% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

22 analis · 2026-10-03

Target rata-rata $294.27 +24,9%

Sekarang Harga saat ini $235.67
Rendah$225.00 Rata-rata$294.27 Tinggi$337.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
JAZZ · -29.1 4.9% · · ·
PRGO $1.92B -1.4 -2.8% -33.5% -38.5% 35.1%
GHRS · -16.1 · · -21.0% ·

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23
Morgan Stanley Menaikkan Target Harga Jazz Pharmaceuticals (JAZZ) Yahoo Finance · 4 bulan, 1 minggu lalu

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Agu 3, 2026